Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Breast cancer: The translation of big genomic data to cancer precision medicine.

Low SK, Zembutsu H, Nakamura Y.

Cancer Sci. 2018 Mar;109(3):497-506. doi: 10.1111/cas.13463. Epub 2017 Dec 30. Review.

2.

Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.

Cani AK, Hovelson DH, Demirci H, Johnson MW, Tomlins SA, Rao RC.

Oncotarget. 2017 Jan 31;8(5):7989-7998. doi: 10.18632/oncotarget.14008.

3.

Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.

Paolillo C, Londin E, Fortina P.

Scand J Clin Lab Invest Suppl. 2016;245:S84-91. doi: 10.1080/00365513.2016.1210331. Epub 2016 Aug 17.

PMID:
27542004
4.

Clinical target sequencing for precision medicine of breast cancer.

Tsuchida J, Rothman J, McDonald KA, Nagahashi M, Takabe K, Wakai T.

Int J Clin Oncol. 2019 Feb;24(2):131-140. doi: 10.1007/s10147-018-1373-5. Epub 2019 Jan 2. Review.

PMID:
30604156
5.

A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.

Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, Symmans WF, Miller VA, Stephens P, Pusztai L.

Oncologist. 2014 May;19(5):453-8. doi: 10.1634/theoncologist.2013-0377. Epub 2014 Apr 7.

6.

Comprehensive genomic sequencing and the molecular profiles of clinically advanced breast cancer.

Ross JS, Gay LM.

Pathology. 2017 Feb;49(2):120-132. doi: 10.1016/j.pathol.2016.11.005. Epub 2016 Dec 26.

PMID:
28034454
7.

Precancer Atlas to Drive Precision Prevention Trials.

Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, Garber JE, Velculescu VE, Disis ML, Wallace DC, Lippman SM.

Cancer Res. 2017 Apr 1;77(7):1510-1541. doi: 10.1158/0008-5472.CAN-16-2346.

8.

Impact of germline and somatic missense variations on drug binding sites.

Yan C, Pattabiraman N, Goecks J, Lam P, Nayak A, Pan Y, Torcivia-Rodriguez J, Voskanian A, Wan Q, Mazumder R.

Pharmacogenomics J. 2017 Mar;17(2):128-136. doi: 10.1038/tpj.2015.97. Epub 2016 Jan 26.

9.

Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study.

Gonçalves A, Bertucci F, Guille A, Garnier S, Adelaide J, Carbuccia N, Cabaud O, Finetti P, Brunelle S, Piana G, Tomassin-Piana J, Paciencia M, Lambaudie E, Popovici C, Sabatier R, Tarpin C, Provansal M, Extra JM, Eisinger F, Sobol H, Viens P, Lopez M, Ginestier C, Charafe-Jauffret E, Chaffanet M, Birnbaum D.

Oncotarget. 2016 Nov 29;7(48):79428-79441. doi: 10.18632/oncotarget.12714.

10.

Genomic medicine and risk prediction across the disease spectrum.

Kotze MJ, Lückhoff HK, Peeters AV, Baatjes K, Schoeman M, van der Merwe L, Grant KA, Fisher LR, van der Merwe N, Pretorius J, van Velden DP, Myburgh EJ, Pienaar FM, van Rensburg SJ, Yako YY, September AV, Moremi KE, Cronje FJ, Tiffin N, Bouwens CS, Bezuidenhout J, Apffelstaedt JP, Hough FS, Erasmus RT, Schneider JW.

Crit Rev Clin Lab Sci. 2015;52(3):120-37. doi: 10.3109/10408363.2014.997930. Epub 2015 Jan 19. Review.

PMID:
25597499
11.

Personalized genomic analyses for cancer mutation discovery and interpretation.

Jones S, Anagnostou V, Lytle K, Parpart-Li S, Nesselbush M, Riley DR, Shukla M, Chesnick B, Kadan M, Papp E, Galens KG, Murphy D, Zhang T, Kann L, Sausen M, Angiuoli SV, Diaz LA Jr, Velculescu VE.

Sci Transl Med. 2015 Apr 15;7(283):283ra53. doi: 10.1126/scitranslmed.aaa7161.

12.

Whole genome sequencing analysis for cancer genomics and precision medicine.

Nakagawa H, Fujita M.

Cancer Sci. 2018 Mar;109(3):513-522. doi: 10.1111/cas.13505. Epub 2018 Feb 26. Review.

13.

Somatic and germline genomics in paediatric acute lymphoblastic leukaemia.

Pui CH, Nichols KE, Yang JJ.

Nat Rev Clin Oncol. 2019 Apr;16(4):227-240. doi: 10.1038/s41571-018-0136-6. Review.

PMID:
30546053
15.

Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.

Syn NL, Yong WP, Goh BC, Lee SC.

Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):911-22. doi: 10.1080/17425255.2016.1196187. Epub 2016 Jun 13. Review.

PMID:
27249175
16.

Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.

Santarpia L, Bottai G, Kelly CM, Győrffy B, Székely B, Pusztai L.

Oncologist. 2016 Sep;21(9):1063-78. doi: 10.1634/theoncologist.2015-0369. Epub 2016 Jul 6. Review.

17.

Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments.

Stover DG, Wagle N.

Curr Oncol Rep. 2015 Apr;17(4):15. doi: 10.1007/s11912-015-0438-0. Review.

18.

Transforming Cancer Prevention through Precision Medicine and Immune-oncology.

Kensler TW, Spira A, Garber JE, Szabo E, Lee JJ, Dong Z, Dannenberg AJ, Hait WN, Blackburn E, Davidson NE, Foti M, Lippman SM.

Cancer Prev Res (Phila). 2016 Jan;9(1):2-10. doi: 10.1158/1940-6207.CAPR-15-0406.

19.

Evaluation of ultra-deep targeted sequencing for personalized breast cancer care.

Harismendy O, Schwab RB, Alakus H, Yost SE, Matsui H, Hasteh F, Wallace AM, Park HL, Madlensky L, Parker B, Carpenter PM, Jepsen K, Anton-Culver H, Frazer KA.

Breast Cancer Res. 2013 Dec 10;15(6):R115. doi: 10.1186/bcr3584.

20.

Mutation based treatment recommendations from next generation sequencing data: a comparison of web tools.

Patel JM, Knopf J, Reiner E, Bossuyt V, Epstein L, DiGiovanna M, Chung G, Silber A, Sanft T, Hofstatter E, Mougalian S, Abu-Khalaf M, Platt J, Shi W, Gershkovich P, Hatzis C, Pusztai L.

Oncotarget. 2016 Apr 19;7(16):22064-76. doi: 10.18632/oncotarget.8017.

Supplemental Content

Support Center